Impact of the CFTR-Potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Bernarde, Cédric ^a   Keravec, Marlène ^a   Mounier, Jérôme ^a   Gouriou, Stéphanie ^a   Rault, Gilles ^b   Férec, Claude ^c,d,e,f   Barbier, Georges ^a   Héry Arnaud, Geneviève ^a,d  

^a UNIVERSITÉ DE BREST   (France)

^b CRCM   (France)

^c French Blood Agency   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

^e FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; RNA 16S; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL STIMULATING AGENT; QUINOLONE DERIVATIVE;

ADOLESCENT; AIRWAY MICROFLORA; AMPLICON; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; GENE MUTATION; HETEROZYGOTE; HUMAN; LUNG CAPACITY; LUNG FUNCTION; MALE; MICROBIAL COMMUNITY; MICROFLORA; MUTATIONAL ANALYSIS; NONHUMAN; PORPHYROMONAS; PREVOTELLA; PYROSEQUENCING; STREPTOCOCCUS; AGONISTS; AMINO ACID SUBSTITUTION; ANAEROBIC GROWTH; BACTERIUM IDENTIFICATION; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; LUNG; LUNG FUNCTION TEST; METABOLISM; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); OTUS; PORPHYROMONAS; POSIBACTERIA; PREVOTELLA; STREPTOCOCCUS; STREPTOCOCCUS MITIS;

ADOLESCENT; AMINO ACID SUBSTITUTION; AMINOPHENOLS; ANAEROBIOSIS; BACTERIAL TYPING TECHNIQUES; CHILD; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG; MICROBIOTA; MOLECULAR TARGETED THERAPY; MUTATION; PORPHYROMONAS; PREVOTELLA; QUINOLONES; RESPIRATORY FUNCTION TESTS; RNA, RIBOSOMAL, 16S; STREPTOCOCCUS; TREATMENT OUTCOME;

EID: 84928914403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124124     Document Type: Article

References (47)

1. Willner D, Furlan M, Haynes M, Schmieder R, Angly FE, Silva J, et al. Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals. PLOS One. 2009; 4:e7370. doi: 10.1371/journal.pone.0007370 PMID: 19816605
2. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLOS One. 2010; 5:e8578. doi: 10.1371/journal.pone.0008578 PMID: 20052417
3. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011; 184:957-963. doi: 10.1164/rccm.201104-0655OC PMID: 21680950
4. Segal LN, Alekseyenko AV, Clemente JC, Kulkarni R, Wu B, Gao Z, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome. 2013; 1:19. doi: 10.1186/2049-2618-1-19 PMID: 24450871
5. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2003; 41:3548-3558. PMID: 12904354
6. Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management. PLOS One. 2012; 7:e36313. doi: 10.1371/journal.pone.0036313 PMID: 22558432
7. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2004; 42:5176-5183. PMID: 15528712
8. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A. 2007; 104:20529-20533. PMID: 18077362
9. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A. 2008; 105:15070-15075. doi: 10.1073/pnas.0804326105 PMID: 18812504
10. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLOS One. 2013; 8:e62917. doi: 10. 1371/journal.pone.0062917 PMID: 23646159
11. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, et al. (2012) Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A. 2010; 109:5809-5814. doi: 10.1073/pnas.1120577109 PMID: 22451929
12. Férec C, Cutting GR. Assessing the Disease-Liability of Mutations in CFTR. Cold Spring Harb Perspect Med. 2012; 2:a009480. doi: 10.1101/cshperspect.a009480 PMID: 23209179
13. Van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Cao D, Neuberger T, et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci 106: 18825-18830. doi: 10.1073/pnas.0904709106 PMID: 19846789
14. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. (2014) Clinical Mechanism of the CFTR Potentiator Ivacaftor in G551D-Mediated Cystic Fibrosis. Am J Respir Crit Care Med 90:175-84.
15. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365:1663-1672. doi: 10.1056/ NEJMoa1105185 PMID: 22047557
16. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013. 187:1219-1225. doi: 10.1164/rccm.201301-0153OC PMID: 23590265
17. Quinn RA, Lim YW, Maughan H, Conrad D, Rohwer F, Whiteson KL. Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung. mBio. 2014; 5: e00956-00913. doi: 10.1128/mBio.00956-14 PMID: 24667707
18. Reznikov LR, Abou Alaiwa MH, Dohrn CL, Gansemer ND, Diekema DJ, Stoltz DA, et al. Antibacterial properties of the CFTR potentiator ivacaftor. J Cyst Fibros. 2014 Sep; 13(5):515-9. doi: 10.1016/j.jcf. 2014.02.004 PMID: 24618508
19. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013. 10:996-998. doi: 10.1038/nmeth.2604 PMID: 23955772
20. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol. 2009; 11(10):2574-2584. doi: 10.1111/j.1462-2920.2009. 01982.x PMID: 19601958
21. Guss AM, Roeselers G, Newton ILG, Young CR, Klepac-Ceraj V, Lory S, et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J. 2011; 5:20-29. doi: 10.1038/ismej. 2010.88 PMID: 20631810
22. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLOS One. 2010; 5:e11044. doi: 10.1371/journal. pone.0011044 PMID: 20585638
23. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, et al. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol. 2006; 44:2601-2604. PMID: 16825392
24. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med. 2008; 177:995-1001. doi: 10.1164/rccm.200708-1151OC PMID: 18263800
25. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLOS One. 2012; 7:e45001. doi: 10.1371/journal.pone.0045001 PMID: 23049765
26. Rivas Caldas R, Boisramé S. Upper aero-digestive contamination by Pseudomonas aeruginosa and implications in Cystic Fibrosis. J Cyst Fibros. 2015 Jan; 14(1):6-15. doi: 10.1016/j.jcf.2014.04.008 PMID: 24933711
27. Maeda Y, Elborn JS, Parkins MD, Reihill J, Goldsmith CE, Coulter WA, et al. Population structure and characterization of viridans group streptococci (VGS) including Streptococcus pneumoniae isolated from adult patients with cystic fibrosis (CF). J Cyst Fibros. 2011; 10:133-139. doi: 10.1016/j.jcf.2010. 11.003 PMID: 21145793
28. Zhao J, Murray S, Lipuma JJ. Modeling the impact of antibiotic exposure on human microbiota. Sci Rep. 2014. 4:4345. doi: 10.1038/srep04345 PMID: 24614401
29. Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, et al. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome. 20131:27.
30. Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, Aitken ML, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci. 2012. 109:13769-13774. doi: 10.1073/pnas.1107435109 PMID: 22872870
31. Rogers GB, Shaw D, Marsh RL, Carroll MP, Serisier DJ, Bruce KD. Respiratory microbiota: addressing clinical questions, informing clinical practice. Thorax. 2015 Jan; 70(1):74-81 doi: 10.1136/thoraxjnl-2014-205826 PMID: 25035125
32. Van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, Daniels TW, et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J. 2011; 5:780-791. doi: 10.1038/ismej.2010.175 PMID: 21151003
33. Peterson SN, Snesrud E, Liu J, Ong AC, Kilian M, Schork NJ, et al. The dental plaque microbiome in health and disease. PLOS One. 2013; 8:e58487. doi: 10.1371/journal.pone.0058487 PMID: 23520516
34. Van Hoogmoed CG, Geertsema-Doornbusch GI, Teughels W, Quirynen M, Busscher HJ, Van der Mei HC. Reduction of periodontal pathogens adhesion by antagonistic strains. Oral Microbiol Immunol. 2008; 23:43-48. doi: 10.1111/j.1399-302X.2007.00388.x PMID: 18173797
35. Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, et al. Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol. 2012; 194:4709-4717. doi: 10.1128/JB.00566-12 PMID: 22753064
36. Crabbé A, Ledesma MA, Nickerson CA. Mimicking the host and its microenvironment in vitro for studying mucosal infections by Pseudomonas aeruginosa. Pathog Dis. 2014; 71:1-19. doi: 10.1111/2049-632X.12180 PMID: 24737619
37. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003; 2:29-34. PMID: 15463843
38. Anonyme. Recommandations pour l'analyse bactériologique des prélèvements d'expectoration chez les patients atteints de mucoviscidose. In: REMIC, Référentiel en Microbiologie Médicale. Paris: Société Française de Microbiologie; 2010. pp. 90-104.
39. Le Gall F, Le Berre R, Rosec S, Hardy J, Gouriou S, Boisramé-Gastrin S, et al. Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis. BMC Microbiol. 2013; 13:143. doi: 10.1186/1471-2180-13-143 PMID: 24088260
40. Nossa CW, Oberdorf WE, Yang L, Aas JA, Paster BJ, Desantis TZ, et al. Design of 16S rRNA gene primers for 454 pyrosequencing of the human foregut microbiome. World J Gastroenterol. 2010; 16:4135-4144. PMID: 20806429
41. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2008; 36:D13-21. PMID: 18045790
42. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010; 7:335-336. doi: 10. 1038/nmeth.f.303 PMID: 20383131
43. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012; 6:610-618. doi: 10.1038/ismej.2011.139 PMID: 22134646
44. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, et al. Ribosomal Database Project: data and tools for high throughput rRNA analysis. Nucleic Acids Res. 2014; 42:D633-642. doi: 10.1093/nar/ gkt1244 PMID: 24288368
45. YilmazP. ParfreyL.W. YarzaP. GerkenJ. PruesseE. QuastC.et al2014The SILVA and " All-species Living Tree Project (LTP)" taxonomic frameworksNucleic Acids Res42D643-64810.1093/nar/gkt1209PMID: 24293649
46. White C. The use of ranks in a test of significance for comparing two treatments. Biometrics. 1952; 8:33-41.
47. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J R Statist Soc B. 1995; 57:239-300.